Xtl Biopharmaceuticals Ltd. · TASE:XTLB
Xtl Biopharmaceuticals — Investor Presentation (November 2018)
13 slides from Xtl Biopharmaceuticals's investor presentation, Nov 8, 2018
Slide 1: XTL Biopharmaceuticals November 2018
www. xtlbio. com XTL Biopharmaceuticals ( NASDAQ: XTLB) ( TASE: XTLB. TA) November 2018
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements in this presentation are forward - looking within the meaning of the Private Securities Litigation Reform Act of 1995 . These statements may be identified by the use of forward - looking words such as "anticipate," "planned," "believe," "forecast," "es
Slide 3: Overview
▪ Current asset, hCDR1, for the treatment of autoimmune diseases: ▪ Strategic shareholding in Intercure ▪ Intercure recently purchased Canndoc , entering the medical cannabis space ▪ XTL holds ~2.5% of Intercure ▪ XTL has ~$9 million in cash and Intercure’s securities ▪ XTL is in the process of iden
Slide 4: hCDR1 Overview
hCDR 1 Overview ▪ Novel compound with unique MoA and robust clinical data ▪ Clinical data in > 400 patients with Systemic Lupus Erythematosus (SLE) o Demonstrated favorable safety profile and well tolerated by patients o “Demonstrated efficacy in … clinically meaningful endpoints” ( Lupus Science &
Slide 5: SLE/Lupus: Market Overview
SLE/Lupus: Market Overview ▪ Prevalence 1 ▪ 1.5 million patients in U.S. ( 5 million worldwide) across various ethnicities/geographies ▪ Vast majority at onset are women / majority between ages of 15 and 45 ▪ Prognosis ▪ Dermatologic & musculoskeletal manifestations are the most common but major org
Slide 6: hCDR1 (Edratide): Clinical Trial History
hCDR 1 ( Edratide ): Clinical Trial History ▪ Three clinical trials completed (by Teva): Phase Ia , Ib and IIb trials ▪ Over 400 patients enrolled in prior trials ▪ Well tolerated and demonstrated favorable safety profile ▪ Phase IIb (PRELUDE) trial (conducted by Teva ) ▪ Did not meet primary endpoi
Slide 7: Secondary Endpoint - BILAG Responder Analysis
Secondary Endpoint - BILAG Responder Analysis (Placebo vs. Edratide 0.5 mg) hCDR 1 Clinical Data – PRELUDE Study ITT Cohort – Predefined Endpoint (p= 0.03 ) Post Hoc Data: Clear trend toward even more substantial effect with reduced steroid use
Slide 8: SS: Market Overview
SS: Market Overview ▪ Prevalence ▪ ~ 0.7 % 1 of U.S. population – estimated 2.5 to 4 million patients 2 ▪ Vast majority at onset are women (at least 9:1 ) 2 ▪ Average age at diagnosis: 40 - 50 years 2 ▪ Market expected to grow to 3.5 million cases globally by 2024 1 ▪ Prognosis ▪ Hallmark symptoms a
Slide 9: hCDR1: Pre-clinical Data on pSS Patients
Confidential * P values calculated from % responses of all tested patients (responders and non responders) as compared to medium= 100 %. ▪ Blood mononuclear cells (PBMC) from blood samples of patients with pSS incubated in - vitro with hCDR 1 and a control peptide ▪ Promising in - vitro/ex - vivo
Slide 10: Strategic Investment in Intercure
Confidential ▪ Intercure recently purchased 100 % of Canndoc , an Israeli licensed producer of Pharma - Grade Cannabis based products, under IMC - GAP/GMP standard ▪ Canndoc has been active in medical cannabis for > 10 years, growing thousands of kilos and providing to thousands of patients and l
Slide 11: Intercure/Canndoc (Competitive Environment)
Confidential Intercure/ Canndoc (Competitive Environment)
Slide 12: Summary
Summary ▪ XTL is looking to develop assets for the treatment of diseases with high unmet medical needs ▪ Its current asset, hCDR 1 , is being developed for the treatment of SLE/lupus and Sjogren’s Syndrome and the company is exploring options for further development ▪ hCDR 1 has robust clinical data
Slide 13: Thank You
Thank You www. xtlbio. com
XTL Biopharmaceuticals — Investor Presentation (November 2018) on 6ix